Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter

Christopher L. Deufel, Keith M. Furutani, Robert A. Dahl, Michael P. Grams, Luke B. McLemore, Christopher Hallemeier, Michelle Neben-Wittich, James A. Martenson, Michael Haddock

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Cholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration. Methods and Materials: This work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations. Results: From 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path. Conclusions: Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.

Original languageEnglish (US)
JournalBrachytherapy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Brachytherapy
Bile Ducts
Catheters
Cholangiocarcinoma
Therapeutics
Equipment and Supplies
Endoscopic Retrograde Cholangiopancreatography
Liver Transplantation
Radiotherapy
Safety
Neoplasms

Keywords

  • Bile duct
  • ERCP
  • High-dose-rate
  • Intraluminal brachytherapy
  • Nasobiliary

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter. / Deufel, Christopher L.; Furutani, Keith M.; Dahl, Robert A.; Grams, Michael P.; McLemore, Luke B.; Hallemeier, Christopher; Neben-Wittich, Michelle; Martenson, James A.; Haddock, Michael.

In: Brachytherapy, 01.01.2018.

Research output: Contribution to journalArticle

Deufel, Christopher L. ; Furutani, Keith M. ; Dahl, Robert A. ; Grams, Michael P. ; McLemore, Luke B. ; Hallemeier, Christopher ; Neben-Wittich, Michelle ; Martenson, James A. ; Haddock, Michael. / Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter. In: Brachytherapy. 2018.
@article{548b2e8172e445548c8a6efe409a1e92,
title = "Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter",
abstract = "Purpose: Cholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration. Methods and Materials: This work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations. Results: From 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path. Conclusions: Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.",
keywords = "Bile duct, ERCP, High-dose-rate, Intraluminal brachytherapy, Nasobiliary",
author = "Deufel, {Christopher L.} and Furutani, {Keith M.} and Dahl, {Robert A.} and Grams, {Michael P.} and McLemore, {Luke B.} and Christopher Hallemeier and Michelle Neben-Wittich and Martenson, {James A.} and Michael Haddock",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.brachy.2018.03.006",
language = "English (US)",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter

AU - Deufel, Christopher L.

AU - Furutani, Keith M.

AU - Dahl, Robert A.

AU - Grams, Michael P.

AU - McLemore, Luke B.

AU - Hallemeier, Christopher

AU - Neben-Wittich, Michelle

AU - Martenson, James A.

AU - Haddock, Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Cholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration. Methods and Materials: This work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations. Results: From 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path. Conclusions: Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.

AB - Purpose: Cholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration. Methods and Materials: This work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations. Results: From 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path. Conclusions: Intraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.

KW - Bile duct

KW - ERCP

KW - High-dose-rate

KW - Intraluminal brachytherapy

KW - Nasobiliary

UR - http://www.scopus.com/inward/record.url?scp=85046861143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046861143&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2018.03.006

DO - 10.1016/j.brachy.2018.03.006

M3 - Article

C2 - 29776892

AN - SCOPUS:85046861143

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

ER -